Recent years have seen a growing evidence of ethnic differences in the frequency of glutathione S-transferase omega 1 (GSTO1) A140D gene polymorphism, which is associated with various cancers such as breast and liver. Until now however, no association has been investigated between the GSTO1 A140D polymorphism and lung cancer. The aim of our study was to see if there was one in the Turkish population. To do that, we identifi ed GSTO1 A140D polymorphism in 214 unrelated healthy individuals and 172 patients with non-small cell lung cancer (NSCLC) using the polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) method. The frequencies of A/A (wild type), A/D (heterozygous mutant), and D/D (homozygous mutant) GSTO1 A140D genotypes in healthy subjects were 48 %, 41 %, and 11 %, respectively. In NSCLC patients they were 48 %, 45 %, and 7 %, respectively. We found no signifi cant association between the GSTO1 A140D gene polymorphism and NSCLC or its histological subtypes, namely squamous cell carcinoma or adenocarcinoma. Furthermore, this polymorphism did not correlate with smoking. Our study is the fi rst to show that the frequency of GSTO1 A140D gene polymorphism in the Turkish population is similar to other Caucasian populations and that this polymorphism is not associated with susceptibility to NSCLC.
Glutathione S-transferases (GSTs) is a superfamily of enzymes that play a key role in the protection of cells against numerous xenobiotics (including carcinogens) and oxidative stress (1) . Human cytosolic GSTs are divided into several classes according to their genetic and biochemical properties such as GST alpha, GST mu, GST theta, GST pi, and GST omega (2) . Glutathione S-transferase omega 1 (GSTO1) is expressed in a wide range of human tissues, including the lungs (3, 4) . It also plays a role in apoptosis (5, 6) and is a potential reservoir of intracellular glutathione (GSH), which protects against cellular oxidative stress (4, 5, 7).
The protective role against cell toxicity can be weakened if enzyme activity is reduced, but the fi ndings related to the GSTO1 gene polymorphism Ala140Asp/A140D are still inconclusive; TanakaKagawa et al. (8) have shown that it signifi cantly reduces thiol transferase activity whereas Whitbread et al. (9) and Board and Anders (10) could not fi nd any significant reduction in the enzyme activity resulting from aspartic acid substitution.
The frequency of GSTO1 A140D seems to vary between races (9, 11-18), but only a few studies investigated this frequency in Caucasians (9, 14, 17, 18) . In the single study of GSTO1 A140D that included the Turkish population, Takeshita et al. (17) observed that its distribution differed from Caucasian populations, and was more similar to African, Eastern Asian, and Brazilian populations. However, this finding is challenged by a great variety in the distribution of the same gene polymorphism even within one population (19) (20) (21) (22) .
Recent studies have established an association between the GSTO1 A140D gene polymorphism and increased risk of breast, hepatocellular, bile duct, and urothelial cancer and acute lymphoblastic leukaemia in children (13, (23) (24) (25) . In addition, several reports suggest that it may be associated with lung cancer in smokers (26) (27) (28) . As about 80 % of the lung cancer patients are non-small cell lung cancer (NSCLC) (29) and cigarette smoke has an important impact on the development of its subtypes such as adenocarcinoma (AC) and squamous cell carcinoma (SCC) (30, 31) , it would be important to know if there were any association between this gene polymorphism and the risk of NSCLC. However, to our knowledge, no data is available in this regard. The aim of our study was therefore to establish the frequency of the GSTO1 A140D polymorphism in the Turkish population and see whether this polymorphism was associated with susceptibility to NSCLC and its histological subtypes.
SUBJECTS AND METHODS
The study population consisted of 214 healthy controls and 172 patients with a histological diagnosis of the primary stage III or IV NSCLC, who were receiving platinum-based chemotherapy, as described elsewhere (32, 33) . All subjects were genotyped for the GSTO1 A140D polymorphism, as determined by the polymorphic analysis of genomic DNA isolated from whole blood using the Promega Corporation (Madison, WI, USA) DNA purifi cation kit and stored at -20 °C until use. GSTO1 A140D (rs4925) was determined with polymerase chain reaction -restriction fragment length polymorphism (PCR-RFLP) method described by Marahatta et al. (13) . Repeated quality control analysis of randomly chosen 10 % of the samples confi rmed a 100 % match.
All subjects were native Turkish Caucasians. Most were from the central Turkey, but also from other Turkish regions to represent the whole country. Healthy unrelated controls were selected from the general population. The exclusion criteria were pregnancy and present or previous history of malignancy. All subjects gave written informed consent, and completed a questionnaire with information on their sex, smoking, occupation, and health history. The study was approved by a local ethics committee.
Statistical analysis
Statistical analysis was performed using the SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). We used Student's t-test to see if the two groups differred in age and smoking (using pack-years as the measure). To establish differences in the distribution of genotype/ allele frequencies between the groups we used the chi-square test and Fisher's exact test where necessary. The chi-square test was also used to see whether the frequency of the GSTO1 A140D polymorphism in either group fi tted the Hardy-Weinberg equilibrium model. Multivariate logistic regression (34) was used to calculate the odds ratios (OR) and 95 % confi dence intervals between the genotypes and lung cancer, adjusted for smoking status, sex, and age. P values less than 0.05 were assumed to be signifi cant.
RESULTS AND DISCUSSION
Allele frequencies and genotype distribution of the GSTO1 A140D polymorphism in our study signifi cantly differ from those of African, Brazilian, and Eastern Asian populations and are similar to other Caucasian populations (Table 1 ). In addition, our results are in contrast with the fi ndings for the Turkish population reported by Takeshita et al. (17) , whose genotype distribution and allele frequencies are similar to those of African, Brazilian, and Eastern Asian populations. This is rather unexpected because polymorphism frequencies of xenobiotic metabolising enzyme genes studied in the Turkish population so far, namely CYP, mEH, and GST, are generally similar to other Caucasian populations (20) (21) (22) 35) . At this stage, we can only speculate about the reasons why our fi ndings differ, as both studies used the same methods, and sample sizes were similar. However, Takeshita et al. (17) have not included important demographic information on their Turkish native-borns such as age, sex, race, and exclusion criteria with respect to the health status. The only information they have provided is that their population included native-borns of the city of Adana in Turkey, whose data they received from a German physician. Characteristics of the study population are presented in Table 2 . As a group, NSCLC patients were older and had more smokers than controls (P<0.05). In addition, they smoked much more than controls (P<0.05). However, we did not fi nd signifi cant differences in the frequency of GSTO1 A/A (wild type), A/D (heterozygous mutant), and D/D (homozygous mutant) genotypes between NSCLC patients and controls, and they remained in the Hardy-Weinberg equilibrium (P=0.456 vs. P=0.379, respectively). No signifi cant difference was also observed between men and women (data not shown).
We also looked into the distribution of GSTO1 genotypes by histological subtypes in NSCLC patients but saw no statistically signifi cant difference between controls and NSCLC or histological subtypes (data not shown). Using multivariate logistic regression (MLR) analysis adjusted for age, sex, and smoking, we established that GSTO1 genotypes presented no risk for overall NSCLC or a particular histological subtype. Likewise, Granja et al. (11) and Marahatta et al. (13) did not fi nd any association between this gene polymorphism and thyroid and colorectal cancers, respectively. Findings are still inconclusive and controversial, as some authors established an increased risk of breast, hepatocellular, bile duct and urothelial cancers, and acute lymphoblastic leukaemia in childhood in GSTO1 A140D mutant allele carries (13, (23) (24) (25) while more recent studies on breast cancer report no such association (36, 37) .
Using MLR, we also established that smoking did not infl uence the relationship between GSTO1 A140D and the risk of NSCLC (Table 3) . However, smoking alone, independent of the genotype, signifi cantly increased the risk of NSCLC (Table 2) . Likewise, Olsen et al. (23) could not detect any interaction between cigarette smoking and GSTO1 A140D in breast cancer, nor could Ada et al. (33) and Schneider et al. (38) establish an association between cigarette smoking and other GST polymorphisms in lung cancer, including NSCLC.
Our study may be limited by the sample size, especially in the analysis of the association between the polymorphism and cancer risk in the histological subtypes. However, this is the fi rst report showing that the frequency of the GSTO1 A140D gene polymorphism in the Turkish population is similar to other Caucasian populations and that this polymorphism is not associated with susceptibility to NSCLC. Further research with a larger sample size is needed to verify this fi nding. 
